KLK3 and prostate carcinoma: KLK3 (also known as prostate-specific antigen) is an outstanding member of the KLKs family as a diagnostic marker and therapeutic target of prostate cancer (PCa), and several medicines are approved and undergone clinical research for the treatment of PCa via targeting KLK3 [29, 30].